Racotumomab
Racotumomab (pronunciation: ra-co-tu-mo-mab) is a vaccine used in the treatment of cancer, specifically lung cancer. It is an anti-idiotype vaccine that targets NeuGcGM3, a ganglioside found in high concentrations on the surface of cancer cells.
Etymology
The name "Racotumomab" is derived from the Latin "Raco", meaning "to fight", and "tumomab", a common suffix for monoclonal antibodies used in cancer treatment.
Usage
Racotumomab is used in the treatment of non-small cell lung cancer (NSCLC). It works by stimulating the body's immune system to attack cancer cells. The vaccine is typically administered in conjunction with other cancer treatments, such as chemotherapy or radiation therapy.
Mechanism of Action
Racotumomab targets a specific antigen known as NeuGcGM3. This antigen is found in high concentrations on the surface of cancer cells, making it an ideal target for immunotherapy. By stimulating the immune system to attack cells expressing this antigen, Racotumomab can help to slow the growth of cancer cells and potentially shrink tumors.
Related Terms
- Vaccine
- Cancer
- Lung cancer
- Anti-idiotype vaccine
- Ganglioside
- Monoclonal antibodies
- Non-small cell lung cancer
- Chemotherapy
- Radiation therapy
- Immunotherapy
- Antigen
External links
- Medical encyclopedia article on Racotumomab
- Wikipedia's article - Racotumomab
This MedicineGPT article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski